Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 2, 2012, Pages 1122-1138

  Saito, Tetsuji ^a   Obitsu, Tetsuo ^a   Kohno, Hiroshi ^a   Sugimoto, Isamu ^a   Matsushita, Takeshi ^a   Nishiyama, Taihei ^a   Hirota, Tomoko ^a   Takeda, Hiroyuki ^a   Matsumura, Naoya ^a   Ueno, Sonoko ^a   Kishi, Akihiro ^a   Kagamiishi, Yoshifumi ^a   Nakai, Hisao ^a   Takaoka, Yoshikazu ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Antagonist; Corticotropin releasing factor 1 receptor

Indexed keywords

2 (2,4 DIMETHYLPHENYL) 5 (1 ETHYLPROPENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE; 2 (2,4,5 TRIMETHYLPHENYL) 5 (1 ETHYLPROPENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE; 2 DIFLUOROMETHOXY 4 METHYPYRIDIN 5 YL DERIVATIVE; 5 (1 ETHYLPROPENYL) 2 (4 METHOXY 2 METHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; ETHYL 2 (2,4 DIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (2,4,5 TRIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (4 ETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (4 METHOXY 2 METHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (4,5 DIMETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (6 DIMETHYLAMINO 4 METHYLPYRIDIN 3 YL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (6 DIMETHYLAMINO 4 METHYLPYRIDIN 3 YL) 4 CHLORO 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 2 (6 DIMETHYLAMINO 4 METHYLPYRIDIN 3 YL) 4 HYDROXY 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 2 (2,4 DIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 2 (2,4,5 TRIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 2 (4 ETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 2 (4 METHOXY 2 METHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 2 (4,5 DIETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 3,7 DIMETHYL 2 (6 METHYL 1,3 BENZODIOXOL 5 YL)PYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 CHLORO 3,7 DIMETHYL 2 (6 METHYLBENZO[1,3]DIOXOL 5 YL)PYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 2 (2,4 DIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 2 (2,4,5 TRIMETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 2 (4 ETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 2 (4,5 DIETHOXY 2 ETHYLPHENYL) 3,7 DIMETHYLPYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; ETHYL 4 HYDROXY 3,7 DIMETHYL 2 (6 METHYL 1,3 BENZODIOXOL 5 YL)PYRROLO[1,2 B]PYRIDAZINE 5 CARBOXYLIC ACID; PYRROLO[1,2 B]PYRIDAZINE DERIVATIVE; PYRROLO[2,1 F]TRIAZIN 4(3H) ONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; NONHUMAN; PROCESS OPTIMIZATION; RAT; RECEPTOR BINDING; SINGLE DRUG DOSE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY;

RATTUS;

EID: 84855809718     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.11.015     Document Type: Article

References (18)

1. M.J. Owens, and C.B. Nemeroff D.J. Chadwick, J. Marsh, K. Ackrill, Corticotropin Releasing-Factor, Ciba Foundation Symposium 172 1993 Wiley Chichester, UK 296
2. W. Vale, J. Spiess, and C. Rivier Science 213 1981 1394
3. F. Holsboer, and M. Ising Eur. J. Pharmacol. 583 2008 350
4. C.F. Hemley, A. McCluskey, and P.A. Keller Curr. Drug Targets 8 2007 105
5. E. Zoumakis, K.C. Rice, P.W. Gold, and G.P. Chrousos Ann. N.Y. Acad. Sci. 1083 2006 239
6. M. Ising, and F. Holsboer Exp. Clin. Psychopharmacol. 15 2007 519
7. A.W. Zobel, T. Nickel, and H.E. Künzel J. Psychiatr. Res. 34 2000 171
8. H.E. Künzel, A.W. Zobel, and T. Nickel J. Psychiatr. Res. 37 2004 525
9. B. Binneman, D. Feltner, S. Kolluri, Y. Shi, R. Qiu, and T. Stiger Am. J. Psychiatr. 165 2008 617
10. P.J. Gilligan, D.W. Robertson, and R. Zaczek J. Med. Chem. 43 2000 1641
11. C.D. Dzierba, R.A. Hartz, and J.J. Bronson Ann. Rep. Med. Chem. 43 2008 3
12. Yoon, T.; Ge, P.; Horvath, R. F.; De Lombert, S.; Hodgetts, K. J. PCT Application Publication WO2001/60806.
13. T. Saito, T. Obitsu, T. Matsui, Y. Nagao, K. Kusumi, N. Matsumura, S. Ueno, A. Kishi, S. Katsumata, Y. Kagamiishi, H. Nakai, and M. Toda Bioorg. Med. Chem. 19 2011 5432
14. T. Saito, T. Obitsu, C. Minamoto, T. Sugiura, N. Matsumura, S. Ueno, A. Kishi, S. Katsumata, H. Nakai, and M. Toda Bioorg. Med. Chem. 19 2011 5955
15. G. Battaglia, E.L. Webster, and E.B. De Souza Synapse 1 1987 572
16. J.F. McElroy, K. Ward, K.L. Zeller, K.W. Jones, P.L. Gilligan, L. He, and S. Lelas Psychopharmacology 165 2002 86
17. Y.-W. Li, G. Hill, H. Wong, N. Kelly, K. Ward, M. Pierdomenico, S. Ren, P. Gilligan, S. Grossman, G. Trainor, R. Taub, J. McElroy, and R. Zaczek J. Pharmacol. Exp. Ther. 305 2003 86
18. Y.-W. Li, L. Fitzgerald, H. Wong, S. Lelas, G. Zhang, M.D. Lindner, T. Wallace, McElroy, N.J. McElroy, P.J. Gilligan, and R. Zaczek CNS Drug Rev. 11 2005 21